Mayank Mamtani Analyst PerformanceSenior Managing Director & Group Head of Healthcare at B. Riley FinancialMayank Mamtani is a stock analyst at B. Riley Financial focused in the medical sector, covering 38 publicly traded companies. Over the past year, Mayank Mamtani has issued 33 stock ratings, including strong buy, buy, and hold recommendations. While full access to Mayank Mamtani's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mayank Mamtani's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings140 Last 7 YearsBuy Recommendations94.78% 127 Buy RatingsCompanies Covered38 Unique Companies Ratings Distribution134RatingsDistribution of strong buy, buy, hold, and sell ratings by Mayank Mamtani.RatingPercentageCount Strong Buy3.7%5 ratings Buy91.0%122 ratings Hold5.2%7 ratings Sell0.0%0 ratingsOut of 134 total stock ratings issued by Mayank Mamtani at B. Riley Financial, the majority (91.0%) have been Buy recommendations, followed by 5.2% Hold and 3.7% Strong Buy.Best & Worst CallsBest Call0000.0%TGTXNov 2019Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%NVAXApr 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ89.5% of companies on NASDAQ34 companiesOTCMKTS5.3% of companies on OTCMKTS2 companiesNYSEAMERICAN2.6% of companies on NYSEAMERICAN1 companyNYSE2.6% of companies on NYSE1 companyMayank Mamtani, an analyst at B. Riley Financial, currently covers 38 companies listed on NASDAQ, OTCMKTS, NYSEAMERICAN and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical37 companies97.4%Manufacturing1 company2.6%Mayank Mamtani of B. Riley Financial specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE23 companies60.5%MED - DRUGS11 companies28.9%BIOTECHNOLOGY2 companies5.3%MED PRODUCTS1 company2.6%PHARMACEUTICAL PREPARATIONS1 company2.6% Mayank Mamtani's Ratings History at B. Riley Financial Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsUNCYUnicycive Therapeutics6/30/2026Reiterated Rating$4.14$22.00Buy$0.0000.00% ROIAAPGAscentage Pharma Group International6/10/2026Initiated Coverage$17.07$45.00Buy$0.0000.00% ROIELTXElicio Therapeutics6/10/2026Initiated Coverage$14.20$27.00Buy$0.0000.00% ROIMGNXMacroGenics4/10/2026Upgrade$3.44$9.00Buy$0.0000.00% ROITBPHTheravance Biopharma4/7/2026Boost Price Target$16.42$17.00Neutral$0.0000.00% ROIHROWHarrow4/7/2026Reiterated Rating$34.91$65.00Buy$0.0000.00% ROILCTXLineage Cell Therapeutics3/25/2026Boost Price Target$1.60$4.00Buy$0.0000.00% ROICLYMClimb Bio3/24/2026Initiated Coverage$6.54$26.00Buy$0.0000.00% ROICLYMClimb Bio3/23/2026Upgrade$6.98Strong-Buy$0.0000.00% ROIARCTArcturus Therapeutics3/18/2026Initiated Coverage$6.39$22.00Buy$0.0000.00% ROISPCX Warning - and Worst News for Stocks in 50 Years (Ad)Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.Learn how to prepare your portfolio for what's coming nextARCTArcturus Therapeutics3/17/2026Upgrade$6.72Strong-Buy$0.0000.00% ROITBPHTheravance Biopharma3/4/2026Reiterated Rating$13.96$14.00Neutral$0.0000.00% ROINKTRNektar Therapeutics2/23/2026Reiterated Rating$71.87$150.00Buy$0.0000.00% ROICYTKCytokinetics1/21/2026Boost Price Target$63.78$108.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals12/11/2025Boost Price Target$552.47$670.00Buy$0.0000.00% ROIIRDOpus Genetics12/10/2025Initiated Coverage$2.39$9.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals12/1/2025Boost Price Target$29.11$42.00Buy$0.0000.00% ROIZYMEZymeworks11/21/2025Reiterated Rating$23.82$40.00Buy$0.0000.00% ROINUVBNuvation Bio11/19/2025Initiated Coverage$4.80$12.00Buy$0.0000.00% ROICYTKCytokinetics11/10/2025Reiterated Rating$61.01$90.00Buy$0.0000.00% ROINVAXNovavax11/10/2025Reiterated Rating$7.23$16.00Buy$0.0000.00% ROITGTXTG Therapeutics11/4/2025Upgrade$33.81Strong-Buy$0.0000.00% ROIZYMEZymeworks10/10/2025Initiated Coverage$16.92$30.00Buy$0.0000.00% ROIHROWHarrow10/1/2025Reiterated Rating$48.18$74.00Buy$0.0000.00% ROIMDGLMadrigal Pharmaceuticals9/29/2025Boost Price Target$439.05$560.00Buy$0.0000.00% ROINKTRNektar Therapeutics9/23/2025Boost Price Target$58.63$105.00Buy$0.0000.00% ROIHROWHarrow9/23/2025Boost Price Target$48.61$70.00Buy$0.0000.00% ROICYTKCytokinetics9/22/2025Boost Price Target$49.04$80.00Buy$0.0000.00% ROITGTXTG Therapeutics9/17/2025Boost Price Target$32.51$55.00Buy$0.0000.00% ROITBPHTheravance Biopharma9/12/2025Initiated Coverage$13.70$28.00Buy$0.0000.00% ROITBPHTheravance Biopharma9/11/2025Upgrade$14.30Strong-Buy$0.0000.00% ROIACTUActuate Therapeutics8/26/2025Initiated Coverage$7.98$20.00Buy$0.0000.00% ROIALTAltimmune8/13/2025Lower Price Target$3.62$18.00Buy$0.0000.00% ROIMNOVMediciNova6/16/2025Upgrade$1.31$5.00Strong-Buy$0.0000.00% ROIMGNXMacroGenics5/20/2025Lower Price Target$1.57$3.00Neutral$0.0000.00% ROIHROWHarrow4/1/2025Lower Price Target$25.23$65.00Buy$00.0000.00% ROIVXRTVaxart3/27/2025Lower Price Target$0.45$2.00Buy$0.0000.00% ROITRVITrevi Therapeutics3/19/2025Reiterated Rating$6.69$20.00Buy$00.0000.00% ROILCTXLineage Cell Therapeutics3/14/2025Lower Price Target$0.52$3.00Buy$0.0000.00% ROIDNLIDenali Therapeutics3/5/2025Reiterated Rating$16.06$35.00Buy$00.0000.00% ROIThe $15 Gold Fund That Pays Up to $1,152/Month (Ad)Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.Discover the gold income fund before the next payout dateARWRArrowhead Pharmaceuticals2/14/2025Reiterated Rating$19.75$38.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyRoyal Bank Of CanadaWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupDeutsche Bank AktiengesellschaftRaymond James FinancialBMO Capital MarketsNational Bank FinancialBerenberg Bank Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
